SS Innovations International (NASDAQ:SSII) and AtriCure (NASDAQ:ATRC) Head-To-Head Review

SS Innovations International (NASDAQ:SSII) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Valuation and Earnings

This table compares SS Innovations International and AtriCure”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49 million	8.82	-$12.13 million	($0.06)	-31.17
AtriCure	$534.53 million	5.50	-$11.45 million	$0.30	192.60

AtriCure has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SS Innovations International and AtriCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-23.73%	-26.77%	-15.01%
AtriCure	2.52%	4.01%	3.03%

Institutional & Insider Ownership

99.1% of AtriCure shares are held by institutional investors. 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for SS Innovations International and AtriCure, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1	0	0	0	1.00
AtriCure	1	4	6	1	2.58

SS Innovations International currently has a consensus price target of $7.00, suggesting a potential upside of 274.33%. AtriCure has a consensus price target of $61.80, suggesting a potential upside of 6.96%. Given SS Innovations International’s higher possible upside, research analysts plainly believe SS Innovations International is more favorable than AtriCure.

Risk and Volatility

SS Innovations International has a beta of -1.52, suggesting that its share price is 252% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Summary

AtriCure beats SS Innovations International on 12 of the 14 factors compared between the two stocks.

About SS Innovations International

AVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.

About AtriCure

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.